The story behind
Kesis & Sisters
Named after the Keres — the sisters of fate in Greek mythology. We believe patients and their clinicians should have ultimate agency over their own destiny. The "Sisters" also represent the specialized AI agents we build to work across our products—relentlessly synthesizing data, guidelines, and literature to empower those decisions.
Turning complexity into clarity — across healthcare
Healthcare decisions are among the most consequential choices anyone faces. Yet the information needed to make them well is often fragmented, rapidly evolving, and buried in technical complexity — whether it's a patient trying to understand a genomic test result, a clinician applying published evidence to the patient in front of them, or a health system evaluating a new therapy.
Kesis & Sisters exists to close that gap. We build intelligent systems that synthesize the latest clinical evidence, genomic data, health economics, and real-world outcomes into clear, defensible guidance — for everyone involved in healthcare's hardest decisions.
Dr. Henry Conter
B.E.Sc., M.D., M.S.F., M.Sc., F.R.C.P.C. Founder & CEOThe tools behind Kesis & Sisters weren't designed in a boardroom. They were built by a physician who spent over a decade making the exact decisions these systems are designed to support.
Henry trained in medical oncology at MD Anderson Cancer Center, then spent six years at Hoffman-La Roche leading global pharmaceutical strategy — first as a Global Medical Director in thoracic oncology, then managing R&D portfolios and pioneering quantitative approaches to drug development decisions from the company's Basel headquarters.
Back in Canada, Henry serves on the Royal College of Physicians & Surgeons financial oversight committee. He previously sat as a voting member on CADTH's pan-Canadian Oncology Drug Review and Cancer Care Ontario's Steering Committee for Cancer Drugs — the bodies that decide which treatments get funded for Canadian patients. He is principal investigator on the FLEX registry, generating real-world genomic profiling data published in JNCI Cancer Spectrum (2025) that directly informs Precision Path.
With degrees spanning mechanical engineering, medicine, finance, and health technology assessment — plus 27 peer-reviewed publications and experience as PI on 17 clinical trials — Henry brings a rare ability to bridge clinical science, technology, and business strategy.
"The gap between what we know from clinical evidence and what actually reaches patients is widening, not narrowing. I built Kesis & Sisters because I've sat on every side of that gap — as a clinician, as a pharma strategist, as a drug reviewer — and I know technology can close it."
What guides everything we build
Evidence-Based
Every recommendation in our platform is traceable to published clinical evidence, NCCN guidelines, or validated genomic data. No black boxes.
Patient-Centered
Technology should serve people, not the other way around. We design for patients first — making complex science accessible and empowering.
Transparent
We show our work. Every clinical assertion is auditable, every data source cited, every algorithm methodology documented. Trust requires transparency.
Rigorous
Clinical decision support carries real responsibility. We hold ourselves to FDA-level audit standards because lives depend on getting this right.
Augmenting clinicians,
never replacing them
We believe AI and clinical decision support technology should amplify the expertise of healthcare providers — not substitute for it. Precision Path synthesizes vast amounts of clinical evidence so clinicians can spend less time searching and more time caring.
Genomic Integration
Native integration with leading genomic risk assays and molecular subtyping platforms to personalize every pathway.
Guideline-First
Built on NCCN 2026 guidelines, updated as evidence evolves — never lagging behind the science.
Full Auditability
Every recommendation includes its evidence source. FDA-level audit trails built in from day one.
Want to work with us?
We're always looking to connect with clinicians, researchers, and organizations who share our mission to improve cancer care through better decision support.